Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05362474 · ClinicalTrials.gov registry record · Phase 3
Targeting Leukotrienes in Kidney Disease
A Phase 3 study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
NCT05362474 is a Phase 3 study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 6 participants.
The verdict
NCT05362474, a Phase 3 study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
Study Summary
Diabetic kidney disease (DKD) is associated with significant morbidity and mortality. Identifying new treatments for DKD to be used alone or in combination with other therapies is a high priority. Inflammation plays a key role in DKD and targeting pro-inflammatory lipid mediators called leukotrienes may represent a promising therapy for DKD. The current proposal will investigate whether montelukast, a leukotriene antagonist, reduces proteinuria and improves vascular function and arterial stiffness in patients with DKD.
Interventions
- DRUG Montelukast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2023-06-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05362474
The ClinicalTrials.gov registry entry for NCT05362474 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Montelukast is the first listed.
NCT05362474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05362474 about?
NCT05362474 is a clinical study titled "Targeting Leukotrienes in Kidney Disease". Diabetic kidney disease (DKD) is associated with significant morbidity and mortality. Identifying new treatments for DKD to be used alone or in combination with other therapies is a high priority. Inflammation plays a key role in DKD and targeting pro-inflammatory lipid mediators called leukotrienes...
What is the current status of trial NCT05362474?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2022-07-01. Estimated completion is 2023-06-20.
What interventions are being tested in trial NCT05362474?
The interventions under investigation include: Montelukast (DRUG).
Who is sponsoring clinical trial NCT05362474?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.